21

July
2008

Vytorin Fails in Heart Study

category: Dafé’s Café - Daily Dose of Medical News,MyDocHub
by Dafé,

Vytorin

New data released Monday, clearly shows that the cholesterol fighter Vytorin sold by Merck & Co Inc and Schering-Plough Corp failed to meet the main goal of improving outcomes in a closely-watched heart study designed to determine whether aggressive cholesterol lowering can lessen the need for surgical replacement of aortic valves. It was also meant to reduce cardiac death and reduce cardiovascular events, including heart attacks.

Basically, another failed drug for Merck & Co Inc and Schering-Plough Corp trying to find another use for Vytorin besides lowering cholesterol.

Related posts:

  1. Study Finds Many Heart Attack Patients Don’t Get Needed Therapies
  2. Polypill for Heart Attacks Coming Soon
  3. Healthy Heart Guide
  4. No Evidence of Garlic’s Purported Benefits
  5. Smelly Herb Stinks for Lowering Cholesterol

|



Comments

Name (required)

Email (required)

Website

Leave a comment

1 Comment so far

  1. Vytorin And New Data | Medicine Blog | 07 April 2011, 06:15

    [...] New data released Monday, clearly shows that the cholesterol fighter Vytorin sold by Merck & Co Inc and Schering-Plough Corp failed to meet the main goal of mydochub.com [...]